Dupilumab

Drug Profile

Dupilumab

Alternative Names: Dupixent; REGN 668; SAR 231893

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Atopic dermatitis
  • Phase III Asthma; Nasal polyps
  • Phase II Eosinophilic oesophagitis

Most Recent Events

  • 08 Dec 2016 Dupilumab is still in phase II trials for Eosinophilic oesophagitis in USA
  • 08 Dec 2016 Preregistration for Atopic dermatitis (Combination therapy, In adults) in European Union (SC)
  • 08 Dec 2016 Preregistration for Atopic dermatitis (Monotherapy, In adults) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top